A New Solution for

VASCULAR DISEASE

A New Solution For

VASCULAR DISEASE

A Large Global Challenge

Peripheral Artery Disease (PAD) is a significant and growing global issue, affecting over 20 Million people in the US, and over 200 Million people worldwide.

Here are some important points to note:

  • PAD and coronary arterial disease (CAD) are related.  People with heart disease have a 1-in-3 risk of developing PAD

  • PAD can cause life-threatening critical limb ischemia which if not treated, can lead to amputation. The death rate after lower limb amputation is 48% at 1 year and a staggering 71% after 3 years

  • Percutaneous transluminal angioplasty (PTA) historically was the standard of care for treating PAD – there is a compelling need to minimize and limit the complications of PTA and improve long-term outcomes

  • Effective plaque modification/vessel preparation is required to optimize and achieve consistent long-term outcomes following drug coated balloon (DCB) or drug-eluting stent (DES) therapies

A Large Global Challenge

Peripheral Artery Disease (PAD) is a significant and growing global issue, affecting over 20 Million people in the US, and over 200 Million people worldwide.

Here are some important points to note:

  • PAD and coronary arterial disease (CAD) are related.  People with heart disease have a 1-in-3 risk of developing PAD

  • PAD can cause life-threatening critical limb ischemia which if not treated, can lead to amputation. The death rate after lower limb amputation is 48% at 1 year and a staggering 71% after 3 years

  • Percutaneous transluminal angioplasty (PTA) historically was the standard of care for treating PAD – there is a compelling need to minimize and limit the complications of PTA and improve long-term outcomes

  • Effective plaque modification/vessel preparation is required to optimize and achieve consistent long-term outcomes following drug coated balloon (DCB) or drug-eluting stent (DES) therapies
LARGE MARKET
0M

people globally suffer from PAD

0M

people in the US suffer from PAD

0M

in the US are diagnosed with PAD every year

LARGE MARKET
0M

people globally suffer from PAD

0M

people in the US suffer from PAD

0M

in the US are diagnosed with PAD every year

IMPROVED OUTCOMES

Physicians seek to:

  • Improve long-term outcomes
  • Improve vessel compliance
  • Minimize vessel damage (barotrauma), reduce dissections and stenting, increase control & predictability
  • Improve therapy delivery to reduce revascularization rates
IMPROVED OUTCOMES

Physicians seek to:

  • Improve long-term outcomes
  • Improve vessel compliance
  • Minimize vessel damage (barotrauma), reduce dissections and stenting, increase control & predictability
  • Improve therapy delivery to reduce revascularization rates
CURRENT APPROACH

The standard of care to open occluded peripheral vessels has been PTA

PTA in peripheral vessels results in a high rate of dissections that require stenting

Peripheral stents often fracture and collapse, causing restenosis

Physicians’ objective is to minimize the use of stents in peripheral vessels

CURRENT APPROACH

The standard of care to open occluded peripheral vessels has been PTA

PTA in peripheral vessels results in a high rate of dissections that require stenting

Peripheral stents often fracture and collapse, causing restenosis

Physicians’ objective is to minimize the use of stents in peripheral vessels

BENEFITS OF FLEX VESSEL PREP
  • Plaque modification / vessel prep prior to treatment optimizes outcomes
  • Preserve physicians’ choice of therapy
  • Seeking clinically effective, cost-efficient, easy-to-use options
  • Effective plaque modification prior to DCB therapy has potential to improve patient outcomes
BENEFITS OF FLEX VESSEL PREP
  • Plaque modification / vessel prep prior to treatment optimizes outcomes
  • Preserve physicians’ choice of therapy
  • Seeking clinically effective, cost-efficient, easy-to-use options
  • Effective plaque modification prior to DCB therapy has potential to improve patient outcomes

Vascular Disease

Peripheral Arterial Disease

View

End Stage Renal Disease (AV Fistulas and Grafts)

View

Vascular Disease

Peripheral Arterial Disease

View

End Stage Renal Disease (AV Fistulas and Grafts)

View

VentureMed Group, Inc. develops and markets innovative endovascular medical devices to solve unmet medical needs in the treatment of PAD and stenoses of AV fistulas and grafts.

VentureMed Group, Inc. is a member of Medical Alley

VentureMed Group, Inc. develops and markets innovative endovascular medical devices to solve unmet medical needs in the treatment of PAD and stenoses of AV fistulas and grafts.

VentureMed Group, Inc. is a member of Medical Alley